Astellas Signs a License Agreement with Frequency Therapeutics to Develop and Commercialize FX-322 for Hearing Loss

 Astellas Signs a License Agreement with Frequency Therapeutics to Develop and Commercialize FX-322 for Hearing Loss

Astellas Signs a License Agreement with Frequency Therapeutics to Develop and Commercialize FX-322 for Hearing Loss

Shots:

  • Frequency to receive $80M up front, up to $545M as development & commercial milestone and royalties on sales in the licensed territory. Frequency will hold the rights to develop & commercialize FX-322 in the US
  • Astellas to get WW rights to develop & commercialize FX-322 (Ex-US) and the companies will jointly conduct global clinical & commercial activities
  • FX-322 is a regenerative therapy that acts by restoring hearing function and activating inner ear progenitor cells in the treatment of sensorineural hearing loss, with the expected onset of its P-II study in Q4’19

Click here to read full press release/ article | Ref: Astellas | Image: Signbox

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post